BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BB-1701’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GlobalData
Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - BB-1701 in Gastroesophageal (GE) Junction Carcinomas

Buy the report

Related Company Profiles

View All

BB-1701 overview

BB-1701 is under development for the treatment of HER2 positive solid tumors including breast cancer, colon cancer, bladder cancer, gastric cancer, urothelial carcinoma and gastroesophageal junction cancer. It is administered by intravenous route.

Bliss Biopharmaceutical (Hangzhou) overview

Bliss Biopharmaceutical (Hangzhou), is a biopharmaceutical company that discovery, development and commercialization of biotherapeutics for rare diseases. The company is headquartered China.

For a complete picture of BB-1701’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.